Date: 2013-08-29
Type of information: R&D agreement
Compound: peptide therapeutics
Company: Zealand Pharma (Denmark) Eli Lilly (USA)
Therapeutic area: Metabolic diseases
Type agreement: R&D
Action mechanism:
Disease: type 2 diabetes, obesity
Details: * On August 29,2013, Zealand Pharma has announced an exclusive peptide drug research and development collaboration agreement with Eli Lilly. Under the agreement, Zealand will collaborate with Lilly in the design and development of potentially first-in-class peptide therapeutics for the treatment of Type 2 diabetes and obesity based on a novel peptide hormone-basedapproach discovered by Lilly. The companies will share in the funding, risk and reward of the program. Future expansion of the collaboration to additional drug targets and disease areas is possible. No financial terms of the agreement have been disclosed.
Financial terms:
Latest news:
